Cysview
Encyclopedia
Cysview is an optical imaging
agent designed to enhance detection of bladder cancer
, in particular carcinoma in situ
(CIS), it reveals lesions that may not be seen with standard white light cystoscopy
. Cysview is marketed in Europe as Hexvix
. Cysview is licensed by GE Healthcare
from Photocure
ASA a Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
The importance and superior efficacy of fluorescence
cystoscopy
compared to white light cystoscopy alone with respect to detection of non-muscle invasive tumours and, specially CIS, is reflected in the 2008 European Association of Urology
Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer, which clearly endorse the technique in its recommendation: "It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures in detecting malignant tumour, particularly CIS".
On May 28, 2010 the US Food and Drug Administration
(FDA) approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
On October 5th 2010 it was announced a newly published publication in Journal of Urology on Hexvix. This publication shows that Cysview guided fluorescence cystoscopy (Hexvix), as an adjunct to conventional white-light cystoscopy, improves the detection of bladder cancer and reduces the rate of early tumour recurrence, compared with white-light cystoscopy alone.
On 10th November 2010 Nature (journal)
published an article claiming that Photodynamic diagnosis (PDD) can improve surgical outcome on bladder cancer.
In April 2011 a new publication on Hexvix® in British Journal of Urology (BJUI) was published. This study confirm the results from a large prospective international study published in the Journal of Urology in November 2010. The results of the trial demonstrate that Hexvix identified lesions, including residual tumours, that were not detected with white light alone in 49% of the patients. It also demonstrated that the improved detection of lesions resulted in a significant reduction in tumour recurrence within 12 months.
On 12th May 2011 it was announced results from a clinical study included retrospective
follow up from 526 patients in a prospective randomized Phase III trial in 28 centers in EU and North America. After a follow-up period up to 5.5 years, the number of patients who have experienced recurrence of their bladder cancer is lower, and the time it takes before the recurrence occurs is longer when they had Hexvix-guided fluorescence cystoscopy.
Optical imaging
Optical imaging is an imaging technique.Optics usually describes the behavior of visible, ultraviolet, and infrared light used in imaging.Because light is an electromagnetic wave, similar phenomena occur in X-rays, microwaves, radio waves. Chemical imaging or molecular imaging involves inference...
agent designed to enhance detection of bladder cancer
Bladder cancer
Bladder cancer is any of several types of malignant growths of the urinary bladder. It is a disease in which abnormal cells multiply without control in the bladder. The bladder is a hollow, muscular organ that stores urine; it is located in the pelvis...
, in particular carcinoma in situ
Carcinoma in situ
Carcinoma in situ is an early form of cancer that is defined by the absence of invasion of tumor cells into the surrounding tissue, usually before penetration through the basement membrane. In other words, the neoplastic cells proliferate in their normal habitat, hence the name "in situ"...
(CIS), it reveals lesions that may not be seen with standard white light cystoscopy
Cystoscopy
Cystoscopy is endoscopy of the urinary bladder via the urethra. It is carried out with a cystoscope.Diagnostic cystoscopy is usually carried out with local anaesthesia...
. Cysview is marketed in Europe as Hexvix
Hexvix
Hexvix is an optical imaging agent developed by the Norwegian pharmaceutical company Photocure ASA. Hexvix is designed to enhance detection of bladder cancer, in particular carcinoma in situ , it reveals lesions that may not be seen with standard white light cystoscopy...
. Cysview is licensed by GE Healthcare
GE Healthcare
GE Healthcare is a division of GE Technology Infrastructure, which is itself a division of General Electric . It employs more than 46,000 people worldwide and is headquartered in Little Chalfont, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment to be headquartered...
from Photocure
Photocure
Photocure ASA is a Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets...
ASA a Norwegian pharmaceutical company that develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
The importance and superior efficacy of fluorescence
Fluorescence
Fluorescence is the emission of light by a substance that has absorbed light or other electromagnetic radiation of a different wavelength. It is a form of luminescence. In most cases, emitted light has a longer wavelength, and therefore lower energy, than the absorbed radiation...
cystoscopy
Cystoscopy
Cystoscopy is endoscopy of the urinary bladder via the urethra. It is carried out with a cystoscope.Diagnostic cystoscopy is usually carried out with local anaesthesia...
compared to white light cystoscopy alone with respect to detection of non-muscle invasive tumours and, specially CIS, is reflected in the 2008 European Association of Urology
European Association of Urology
The European Association of Urology is a non-profit organisation committed to the representation of urology professionals worldwide...
Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer, which clearly endorse the technique in its recommendation: "It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures in detecting malignant tumour, particularly CIS".
On May 28, 2010 the US Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
(FDA) approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
On October 5th 2010 it was announced a newly published publication in Journal of Urology on Hexvix. This publication shows that Cysview guided fluorescence cystoscopy (Hexvix), as an adjunct to conventional white-light cystoscopy, improves the detection of bladder cancer and reduces the rate of early tumour recurrence, compared with white-light cystoscopy alone.
On 10th November 2010 Nature (journal)
Nature (journal)
Nature, first published on 4 November 1869, is ranked the world's most cited interdisciplinary scientific journal by the Science Edition of the 2010 Journal Citation Reports...
published an article claiming that Photodynamic diagnosis (PDD) can improve surgical outcome on bladder cancer.
In April 2011 a new publication on Hexvix® in British Journal of Urology (BJUI) was published. This study confirm the results from a large prospective international study published in the Journal of Urology in November 2010. The results of the trial demonstrate that Hexvix identified lesions, including residual tumours, that were not detected with white light alone in 49% of the patients. It also demonstrated that the improved detection of lesions resulted in a significant reduction in tumour recurrence within 12 months.
On 12th May 2011 it was announced results from a clinical study included retrospective
Retrospective
Retrospective generally means to take a look back at events that already have taken place. For example, the term is used in medicine, describing a look back at a patient's medical history or lifestyle.-Music:...
follow up from 526 patients in a prospective randomized Phase III trial in 28 centers in EU and North America. After a follow-up period up to 5.5 years, the number of patients who have experienced recurrence of their bladder cancer is lower, and the time it takes before the recurrence occurs is longer when they had Hexvix-guided fluorescence cystoscopy.